A valid prescription requires a telehealth consultation with a licensed provider. No medication is dispensed without clinical evaluation.

CJC-1295 / Ipamorelin 5mg/5mg
Balanced Dual Secretagogue Formulation

Compound Specifications
CJC-1295 / Ipamorelin 5mg/5mg
Balanced Dual Secretagogue Formulation
An equal 1:1 ratio dual-peptide secretagogue combining CJC-1295 (5mg) and Ipamorelin (5mg) in a 3mL vial. Formulated for balanced GHRH and ghrelin receptor stimulation to support natural endocrine output.
Synergistically activates dual distinct somatotroph pathways: GHRH receptor triggering by CJC-1295 paired with GHRP-mediated calcium influx by Ipamorelin.
Documented Therapeutic Benefits
Results may vary. Individual outcomes depend on adherence, baseline health, and other factors.
Administer subcutaneously at bedtime 5 nights on, 2 nights off.
Frequently Asked Clinical Questions
How does the 5mg/5mg ratio differ from 6mg/12mg?
The 5mg/5mg equal-ratio blend provides symmetrical GHRH and GHRP signaling in a 3mL format, tailored for patients seeking balanced secretagogue stimulation.